10 South Colonnade
27th April 2021
Dear Ms Ambrose,
Our Ref: FOI 21/315
Thank you for your email dated 30th March 2021, where you asked for the following information:
A) the latest number of deaths that have occurred within 28 days of having the covid vaccine (since
the start of inoculation)
B) the cause of deaths for those people and the prevalence of each cause
Suspected adverse drug reactions can be reported via the Yellow Card scheme at any time after the
side effect has occurred. Additionally, the time frame from when the patient received the vaccine to
experiencing a suspected side effect is not always provided by the reporter. We review all reports of
death regardless of the time to onset from receiving a medicine or vaccine. Our routine ADR summary
publication provides information on all reports received associated with COVID-19 vaccines including
We follow-up all fatalities where permission has been provided to do so for further information
including post-mortem details if available. As with any serious suspected ADR, reports with a fatal
outcome are fully evaluated by the MHRA, to consider whether the vaccine (or medicine) may have
caused the event, or whether the event and fatal outcome were likely to be purely coincidental and
due to underlying illness.
I hope the information provided is helpful, but if you are dissatisfied with the handling of your request,
you have the right to ask for an internal review. Internal review requests should be submitted within
two months of the date of this response; and can be addressed to this email address.
Vigilance and Risk Management of Medicines Division
The MHRA information supplied in response to your request is subject to Crown copyright. The FOIA only entitles you to
access to MHRA information.
For information on the reproduction or re-use of MHRA information, please visit https://www.gov.uk/government/publications/reproduce-or-re-use-mhra-information/reproduce-or-re-use-mhra-information
If you have a query about this email, please contact us. If you are unhappy with our decision, you may ask for it to be
reviewed. That review will be undertaken by a senior member of the Agency who has not previously been involved in your
request. If you wish to pursue that option please write to the Communications Directorate, Medicines and Healthcare
products Regulatory Agency, (via this email address). After that, if you remain dissatisfied, you may ask the Information
The Information Commissioner’s Office
The information supplied in response to your request is the copyright of MHRA and/or a third party or parties, and has been
supplied for your personal use only. You may not sell, resell or otherwise use any information provided without prior
agreement from the copyright holder.